Claims for Patent: 11,872,314

Summary for Patent: 11,872,314

Title:	Pharmaceutical compositions
Abstract:	Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.
Inventor(s):	Shunji Haruta
Assignee:	Shin Nippon Biomedical Laboratories Ltd
Application Number:	US17/005,647
Patent Claims:	1. A method, comprising intranasally administering to a subject an intranasal pharmaceutical powder composition, wherein the intranasal pharmaceutical powder composition comprises particles that comprise an active agent, a carrier, and at least one member selected from the group consisting of a thickening agent, a pH adjusting agent, a sugar alcohol, and any combination thereof, and wherein: the active agent comprises dihydroergotamine (DHE) or a pharmaceutically acceptable salt thereof, indomethacin or a pharmaceutically acceptable salt thereof, or testosterone or a pharmaceutically acceptable salt thereof; the carrier comprises a microcrystalline cellulose, wherein the microcrystalline cellulose is at least partially coated with the active agent; at least about 20 percent by weight of the active agent in the particles is amorphous as determined by X-ray diffraction; wherein the particles are prepared by spray-drying with the microcrystalline cellulose; when the active agent has a crystalline form, a solubility of the active agent in a crystalline form in an aqueous liquid ranges from about 0.1 μg/mL to about 1 mg/mL in water at a temperature of 37±0.5° C.; the particles have an average particle size of from about 10 microns to about 300 microns, as measured by laser diffraction; and the administering improves a pharmacokinetic parameter of the active agent by at least about 15%, compared to an intranasal administration of a corresponding composition that comprises the active agent in a crystalline form when administered intranasally to a comparable human subject, as measured by a same method, and wherein the pharmacokinetic parameter comprises AUC0-10 min, AUC0-15 min, AUC0-30 min, Cmax, or any combination thereof. 2. The method of claim 1, wherein the administration is for at least: one day, two days, three days, four days, five days, six days, one week, one month, or one year. 3. The method of claim 1, wherein the administration occurs 1, 2, 3, 4, 5, 6, 7, or 8 times daily. 4. The method of claim 1, wherein the intranasal pharmaceutical powder composition is in a single unit dose. 5. The method of claim 1, wherein the intranasal pharmaceutical powder composition is in a unit dose of from about 5 mg to about 50 mg. 6. The method of claim 5, wherein the unit dose is from about 20 mg to about 30 mg. 7. The method of claim 5, wherein the unit dose comprises from about 0.1 mg to about 10 mg of the active agent. 8. The method of claim 7, wherein the active agent is present in an amount of from about 4 mg to about 10 mg in the unit dose. 9. The method of claim 1, wherein the subject is a primate. 10. The method of claim 9, wherein the subject is a human. 11. The method of claim 9, wherein the subject is a monkey. 12. The method of claim 1, wherein the microcrystalline cellulose has an average particle size of from about 20 μm to about 50 μm. 13. The method of claim 1, wherein the intranasal pharmaceutical powder composition comprises the sugar alcohol, and wherein the sugar alcohol is mannitol, glycerol, galactitol, fucitol, inositol, volemitol, maltotriitol, maltoetetraitol, polyglycitol, erythritol, threitol, ribitol, arabitol, xylitol, allitol, dulcitol, glucitol, sorbitol, altritol, iditol, maltitol, lactitol, isomalt, or any combination thereof. 14. The method of claim 1, wherein the intranasal pharmaceutical powder composition comprises the thickening agent, and wherein the thickening agent is hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose, methyl cellulose, carboxymethylcellulose calcium, sodium carboxymethylcellulose, colloidal silicon dioxide, gelatin, alginic acid, sodium alginate, xanthan gum, acacia, guar gum, locust bean gum, gum tragacanth, starch, methylcellulose, polyvinylpyrrolidone, or any combination thereof. 15. The method of claim 13, wherein the sugar alcohol comprises mannitol. 16. The method of claim 14, wherein the thickening agent comprises hydroxypropyl methylcellulose (HPMC). 17. The method of claim 1, wherein the particles are prepared by spray-drying the active agent onto the microcrystalline cellulose. 18. The method of claim 1, wherein the particles are prepared by spray-drying the microcrystalline cellulose along with the active agent.